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Schlafen (SLFN/Slfn) family members have been investigated for their involvement in fundamental cel-
lular processes including growth regulation, differentiation and control of viral replication. However,
most research has been focused on the characterization of Slfns within the murine system or in human
cell lines. Since little is known about SLFNs in primary human immune cells, we set out to analyze the
expression and regulation of the six human SLFN genes in monocytes, monocyte-derived dendritic cells
(moDCs) and T cells. Comparison of SLFN gene expression across these three cell types showed high
mRNA expression of SLFN11 in monocytes and moDCs and high SLFN5 expression in T cells, indicating
functional importance within these cell types. Differentiation of monocytes to moDCs leads to the gra-
dual upregulation of SLFN12L and SLFN13 while SLFN12 levels were decreased by differentiation stimuli.
Stimulation of moDCs via human rhinovirus, lipopolysaccharide, or IFN-α lead to strong upregulation of
SLFN gene expression, while peptidoglycan poorly stimulated regulation of both SLFNs and the classical
interferon-stimulated gene MxA. T cell activation was found to downregulate the expression of SLFN5,
SLFN12 and SLFN12L, which was reversible upon addition of exogenous IFN-α. In conclusion, we
demonstrate, that SLFN gene upregulation is mainly dependent on autocrine type I interferon signaling in
primary human immune cells. Rapid decrease of SLFN expression levels following T cell receptor sti-
mulation indicates a role of SLFNs in the regulation of human T cell quiescence.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Schlafen (Slfn, SLFN) family was initially reported as a family
of growth-regulatory genes in mice that is differentially regulated
during thymocyte development and T cell activation [1]. The name
„Schlafen“ is derived from a German word, meaning “to sleep” and
refers to the G0/G1 cell cycle arrest that was observed upon ectopic
expression of prototypic Slfn1 in NIH-3T3 ﬁbroblasts [1]. Slfn genes
have been evolutionarily conserved across species with gene
duplications giving rise to ten murine (Slfn) and six human (SLFN)
family members [2]. All Slfn proteins share a core region harboring
an divergent AAA domain, which is presumed to confer ATPaseB.V. This is an open access article u
oDC, monocyte-derived den-
.g. IFN-α); ISG, interferon-
oglycan; TLR, Toll-like
at (J. Stöckl).activity [2]. Adjacent to the N-terminal part of this domain lies the
so-called “Slfn-box”, which is a domain of unknown function
showing partial homology to the conserved domain signature
COG2865 found in putative transcriptional regulators and heli-
cases [3–5]. Slfns are typically divided into three subgroups
depending on size and domain composition. Subgroup I comprises
short Slfn isoforms in the range of 37–42 kDa, while Subgroup II
Slfns are 58–68 kDa in size. Subgroup III contains the largest Slfn
family members (100–104 kDa), which are also characterized by
the presence of signature motifs homologous to the helicase
superfamily I and to the UvrD DNA helicase superfamily [3,6].
While murine Slfns are distributed across all three subgroups,
humans only possess SLFNs classiﬁed as subgroup II (SLFN12,
SLFN12L) and subgroup III (SLFN5, SLFN11, SLFN13, SLFN14) [6].
Slfn5/SLFN5 and Slfn14/SLFN14 are the only one-to-one orthologs
shared by mice and men, which is in line with the rapid evolution
of this gene family, especially in the mouse [2,7,8].
Several studies have implicated at least some Slfn family
members as regulators of cellular growth processes and/ornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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how these Slfns interfere with the cell cycle machinery. While one
study demonstrated that Slfn1 mediates growth-inhibitory effects
via inhibition of cyclin D1 promoter activity [9], another one was
unable to reproduce these ﬁndings [16]. Other observations point
to a general role of Slfns in immune processes, since Slfns are
preferentially expressed in lymphoid tissues [1], are inducible by
type I interferons [10,13,17], TLR ligands [7,18] or bacterial infec-
tion [3] and have been demonstrated to interfere with viral
replication [17,19]. At present, most research performed on Slfn
family members has been focused on murine Slfns. With the
exception of SLFN11, human SLFNs have not been extensively
studied. SLFN11 was recently identiﬁed as an HIV-1 restriction
factor, which limits retroviral replication by inhibiting the pro-
duction of HIV-1 proteins by binding of cellular tRNAs [17]. Con-
sistent with this ﬁnding, SLFN11 expression is elevated in HIV-1
infected patients that are capable of suppressing viral replication
[20]. A role for SLFN11 has also been suggested in cancer therapy,
since its expression was positively correlated with the growth-
inhibitory action of topoisomerase inhibitors on human cancer
cells and shows a positive correlation with tumor-free survival in
Ewing's sarcoma patients [21–25]. Further evidence regarding a
function of Slfns in immune responses is also provided by the
existence of Slfn-like genes in orthopoxviruses, where they have
been suggested to serve as viral virulence factors [2,26]. Berger
et al. have also reported severe susceptibility to bacterial or viral
infection in mice with a loss-of-function mutation in Slfn2 due to a
loss of cellular quiescence in monocytes and T cells [27].
Since little is known about the expression and regulation of
SLFN genes in primary human immune cells, we sought to char-
acterize the expression of the six human SLFN genes in cell types at
the interface between the innate and adaptive immune system.
Thus, we selected primary CD14þ monocytes, which give rise to
monocyte-derived dendritic cells (moDCs) in vivo under inﬂam-
matory conditions [28] and T lymphocytes that are activated by
these cells upon encounter with their cognate peptide-MHC
complex. In this study, we show that human SLFNs are regulated
during the differentiation of monocytes to moDCs and are indu-
cible in these cells mainly via type I interferon signaling. Fur-
thermore, we report moderate downregulation of several SLFN
family members during the activation of primary human T cells.2. Materials and methods
2.1. Media, reagents and chemicals
Cells were maintained in RPMI 1640, supplemented with 2 mM
L-glutamine, (both Gibco Ltd., Paisley, Scotland), 100 U/mL peni-
cillin, 100 mg/mL streptomycin (PAA Laboratories, Austria) and 10%
FCS (Gibco, Paisley, Scotland). Recombinant human GM-CSF and
IL-4 were kindly provided by Novo Nordisk A/S (Bagsværd, Den-
mark). IFN-α2b was obtained from PBL Biomedical Laboratories
(Piscataway, NJ). Lipopolysaccharide (LPS) from E. coli 0127:B8 and
peptidoglycan (PGN) derived from S. aureus were purchased from
Sigma-Aldrich (St. Louis, MO). Human rhinovirus serotype 14
(HRV14) was prepared as described [29]. CD3 (clone OKT3) and
CD28 (clone 15E8) antibodies were from Janssen-Cilag (Vienna,
Austria) and Caltag Laboratories (Burlingame, CA), respectively.
2.2. Primary cell isolation
Buffy coats from healthy donors were obtained from either the
University Clinic for Blood Group Serology and Transfusion Med-
icine, Medical University of Vienna or the Austrian Red Cross (both,
Vienna, Austria). Peripheral blood mononuclear cells (PBMCs)were isolated from heparinized buffy coats via standard density
gradient centrifugation using Ficoll-PaqueTM Plus (GE Healthcare,
Chalfont St. Giles, UK). T cells and monocytes were puriﬁed from
PBMCs using the MACS system (Miltenyi Biotec, Bergisch Glad-
bach, Germany) as described previously [30]. Brieﬂy, T cells (total
CD3þ cells) were obtained via depletion of CD11b, CD14, CD16,
CD19, CD33, and MHC class II-positive cells. Enrichment of
monocytes was achieved via positive selection using biotinylated
CD14 mAb [30].
2.3. Generation and stimulation of moDCs
Generation of moDCs was performed by culturing puriﬁed
monocytes for 6 days with a combination of GM-CSF (50 ng/ml)
and IL-4 (35 ng/ml). On day 6 of differentiation, moDCs were sti-
mulated using 1 TCID50/cell of HRV14, 100 U/ml IFN-α2b, 1 μg/ml
LPS or 10 μg/ml PGN.
2.4. T CELl proliferation
Puriﬁed T lymphocytes were activated at 2105 cells/well in
MAXISORP Nunc-Immuno plates (Thermo Scientiﬁc, Waltham,
MA) using plate-bound anti-CD3 or a combination of anti-CD3 and
anti-CD28 in the presence or absence of 100 U/ml IFN-α2b. Anti-
bodies were coated overnight at 4 °C, using a concentration of
2 μg/ml for each antibody. T cell proliferation was monitored via
[methyl-3H] thymidine (PerkinElmer/New England Nuclear Cor-
poration, Wellesley, MA) incorporation. On day 3 of activation,
cells were pulsed with 0.05 mCi/well of [methyl-3H] thymidine
18 h prior harvesting. Detection was performed using a microplate
scintillation counter (Topcount; Packard, Meriden, CT) as counts
per minute (CPM). All assays were performed in triplicates.
2.5. Quantitative real-time PCR (qPCR)
1–2106 cells per sample were lysed in peqGOLD TriFast
(Peqlab, Erlangen, Germany). Subsequently, total RNA was isolated
via chloroform extraction according to the manufacturer's
instructions. Reverse transcription of mRNA was performed using
RevertAid H Minus Reverse Transcriptase (Thermo Scientiﬁc) and
oligo (dT)18 primers. cDNA was stored at 20 °C until use. qPCR
was performed using SYBR Green qPCR master mix (Quanta
Biosciences, Gaithersburg, MD) on a CFX96 Real-Time PCR detec-
tion system (Bio-Rad, Hercules, CA). For ampliﬁcation, a standard
program was applied (10 min at 95 °C, 40 cycles of each 15 s at
95 °C, 15 s at 60 °C and 45 s at 72 °C). Primers used in this study
are depicted in Table 1. Primer sequences for CD3E and HPRT have
been described before [7,31]. All primers were synthesized by
Sigma-Aldrich (Steinheim, DE).
2.6. Data analysis
Data analysis for qPCR was performed using Bio-Rad CFX
Manager Software (Bio-Rad, Hercules, CA). Ampliﬁcation speciﬁ-
city was determined via melting curve analysis and/or agarose gel
electrophoresis. Amplicons yielding Ct values of 31 or higher were
deﬁned to be undetectable (UD). Relative expression was calcu-
lated in Microsoft Ofﬁce Excel (Microsoft, Redmond, WA) using the
2ΔΔCt method [32]. Data was plotted and statistically analyzed
using GraphPad Prism software (La Jolla, CA). Unpaired, two-tailed
Student's t-test was performed, considering p-values o0.05 as
statistically signiﬁcant.
Table 1
Primers used in this study.
Target mRNA Forward primer 50-30 Reverse primer 50-30
CD3E [31] TGAGGGCAAGAGTGTGTGAG TCCTTGTTTTGTCCCCTTTG
GAPDH CGACCACTTTGTCAAGCTCA AGGGGAGATTCAGTGTGGTG
HPRT [7] TCAGGCAGTATAATCCAAAGATGGT AGTCTGGCTTATATCCAACACTTCG
KLF2 CTACACCAAGAGTTCGCATCTG AGTTGCAGTGGTAGGGCTTC
MxA ACCTGATGGCCTATCACCAG TTCAGGAGCCAGCTGTAGGT
SLFN5 AATTGCCCACAAGAGAATGG AGCGTTTCTGCTGCTCTTTC
SLFN11 CCTCCCCTTAGCAGACCAGT TTCCCCGAAAGAAAGGTTG
SLFN12 CATTACCTGCTCCCCACAGT GCCCTTTCTGACAGAGTCCA
SLFN12L TTGACCGAGAAGGAATGGAT GCAGAAGGTTTTTGGAGCAC
SLFN13 GACGCAGATCCAGAGTTTCC AAATGTCCTGGTGGAACTGG
SLFN14 TCAGTCAGCTCCTCCCAGTT CAAGGATGTATCAGGGTCTTCA
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3.1. Basal expression levels of SLFNs in primary human monocytes,
moDCs and T cells
Since little is known about the expression of SLFNs in primary
human immune cells, we analyzed basal mRNA expression levels
of the six human SLFN family members in unstimulated mono-
cytes, moDCs and T lymphocytes. While SLFN5 and SLFN11 showed
the most robust expression across all three cell types, SLFN14 was
only detectable at low levels in T cells, and was undetectable in
monocytes and moDCs (Fig. 1). SLFN5, SLFN12L and SLFN13
expression was highest in T cells, whereas SLFN11 were more
prominently expressed in monocytes and moDCs, although these
differences did not reach statistical signiﬁcance due to high inter-
donor variability for SLFN11 expression especially in monocytes
(Fig. 1). Basal levels of SLFN12L and SLFN13 expression were rela-
tively low in monocytes, but appeared to be upregulated during
differentiation into moDCs. Conversely, the levels of SLFN12 mRNA
were decreased in moDCs vs. monocytes (Fig. 1). To determine the
kinetics of this regulation, we analyzed the expression of SLFN
mRNA in monocytes stimulated with IL-4/GM-CSF over a six days
time course. In line with our previous results, SLFN5 and SLFN11
expression was only slightly altered during moDC differentiation
(Fig. 2). SLFN12 expression was markedly reduced, starting from
day one of differentiation and was maintained at this level during
the entire observation period (Fig. 2). Conversely, expression of
SLFN12L and SLFN13 mRNA was induced during differentiation,
with induction starting at day 2 and day 4, respectively (Fig. 2).
3.2. SLFNs are induced in moDCs upon autocrine type I interferon
signaling
SLFN genes have been investigated in the context of viral
infection before [17,19]. DCs are sentinel cells, that are among the
ﬁrst cells to sense viral infection at anatomical interfaces with the
external environment [33]. Thus, we hypothesized, that viral
infection of moDCs would induce transcriptional activation of
SLFNs. We chose for our studies HRV14, which is a human-speciﬁc
pathogen, that is able to enter moDCs, but does not replicate in
these cells [34]. We inoculated moDC cultures with HRV14 and
analyzed the mRNA levels of all known human SLFN genes in
untreated cells and at 4 and 24 h (hours) after the inoculation with
the virus. Most SLFNs displayed induction kinetics similar to the
classical interferon-stimulated gene (ISG) MxA [35], showing only
slight induction after 4 h and a marked increase after 24 h
(Fig. 3A), indicating that their induction is mainly dependent on
autocrine type I interferon signaling. To further explore this con-
cept, we treated moDCs with IFN-α over the same time course.
However, unlike infection with HRV14, direct addition of this typeI interferon induced strong induction of SLFNs already at the early
time point and was found to be decreased by 24 h (Fig. 3B). Again,
SLFN gene expression closely mirrored the expression pattern of
MxA, although the strength of the induction is not comparable to
the latter in terms of fold induction (Fig. 3B).
We then investigated the effect of the classical pathogen
associated molecular patterns LPS and PGN on SLFN gene expres-
sion, which are potent and poor inducers of IFN-β, respectively
[36–38]. As expected, TLR4 stimulation of moDCs via LPS strongly
induced MxA transcription, which was maximal after 4 h and
already declined at the 24 h time point (Fig. 4A). Interestingly, this
pattern of induction was not shared by all SLFNs, since SLFN12L and
SLFN13mRNAs were found to be further upregulated at 24 h, while
SLFN12 transcripts appeared to stabilize at the levels observed
after 4 h (Fig. 4A).
Conversely, addition of PGN to cultured moDCs only modestly
enhanced transcription of the MxA gene, which returned to basal
levels by 24 h (Fig. 4B). Most SLFNs shared this relatively weak
transcriptional induction, whereas SLFN12 was found to be con-
sistently downregulated at both of the two time points observed
(Fig. 4B).
3.3. SLFN genes are downregulated during T cell activation
Murine and rat Slfns are regulated during thymocyte develop-
ment and T cell activation [1,3,39]. The exit of T lymphocytes out of
a quiescent state during activation is an active process, that not
only requires expression of growth-promoting factors, but also
suppression of quiescence-enforcing genes [40]. Hypothesizing,
that SLFNs might be involved in the exit or maintenance of human
T cell quiescence, we activated primary T lymphocytes with plate-
bound anti-CD3 or a combination of CD3 and CD28 antibodies and
analyzed SLFN gene expression via qPCR. We could detect
expression of all human SLFNs in isolated T cells, albeit SLFN14
transcripts were found to be expressed at low levels and could not
be reproducibly quantiﬁed upon culture of the cells (Fig. 1 and
data not shown). Most SLFN genes were downregulated after
activation, independent of the presence of costimulation (Fig. 5A).
While SLFN5 appeared to be gradually downregulated during the
24 h time course, SLFN12 as well as SLFN12L were downregulated
by roughly 50% already 6 h after activation and were maintained at
these levels for the entire observation period (Fig. 5A). SLFN11 and
SLFN13 expression was not consistently altered during human T
cell activation. Comparing the regulation of SLFNs to the classical T
cell quiescence factor KLF2[41,42], we found that activation
mediated down-regulation of SLFNs was less pronounced, since
KLF2mRNA levels were reduced by 80% already 6 h after activation
and were further reduced by 24 h post stimulation (Fig. 5A)
Since type I interferon signals strongly induced SLFN gene
expression in moDCs, we hypothesized that these signals would
UD UD
Fig. 1. Basal SLFN gene expression in human monocytes, moDCs and T cells. Levels of the indicated SLFN mRNAs were quantiﬁed via qPCR in isolated CD14þ monocytes (n¼4),
moDCs on day 6 of differentiation (n¼3) and CD3þ T cells (n¼3). Data are expressed relative to the reference gene HPRT. UD, undetectable. Mean7SEM are given. *po0.05,
**po0.01 and ***po0.001 (unpaired t-test).
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we found that addition of exogenous IFN-α induced transcript
levels of most SLFNs to or above those of unstimulated cells
(Fig. 5B) indicating a dominance of type I interferon signaling over
T cell activating stimuli at least in this setting. Interestingly, the
expression of SLFN11 and SLFN13was not much altered by IFN-α in
activated T cells suggesting different induction thresholds in these
cells (Fig. 5B). However, SLFN gene induction did not correlate
with reduced T cell growth, since we found no differences in the
proliferation of T cells activated in the presence or absence of IFN-
α (Fig. 5C).4. Discussion
Since their discovery in the late 1990s, Slfn/SLFN family
members have been investigated for their involvement in funda-
mental cellular processes including growth regulation, differ-
entiation and control of viral replication. While Slfns have been
studied also in non-hematopoietic cells, several studies have
highlighted their role in cells of the immune system
[1,3,7,18,27,39]. However, most of this work has been performed
with rodent cells or human tumor cell lines, while little is still
known about the role of SLFNs in primary human cells.
Monocyte to moDC differentiation (days) 
Fig. 2. Regulation of SLFNs during monocyte to dendritic cell differentiation. Monocytes were differentiated to moDCs using 50 ng/ml GM-CSF and 35 ng/ml IL-4. Gene
expression was monitored over a 6 days time course. Cells were harvested at the indicated days and mRNA expression of SLFN genes was determined via qPCR. Expression
values were calculated relative to HPRT as a reference gene and normalized to unstimulated cells. Data is representative of two different donors. Error bars indicate
mean7SD of technical replicates. Note, that for some bars SD is too small to be discernible.
A. Puck et al. / Results in Immunology 5 (2015) 23–32 27Differentiation of monocytes to moDCs via IL-4 and GM-CSF
leads to the differential regulation of several hundred genes
including transcription factors, cytokines and cell surface receptors
[43], indicating that a multitude of factors is involved in the
functional specialization of these cells. Thus, downregulation of
SLFN12 as well as upregulation of SLFN12L and SLFN13 point to
different requirements of these molecules in moDC function.
Murine Slfn4 was previously reported as a modulator of myelo-
poiesis, which is downregulated upon CSF-1 mediated bone
marrow-derived macrophage differentiation [7]. Since human
SLFN12 shares the highest sequence identity with murine Slfn4,
our data suggest similar roles for this molecule in the differ-
entiation of human myeloid cells, which is consistent with pre-
vious observations [7].
Dendritic cells are key players in both, innate and adaptive
immune responses against viruses [44]. However, many viruseshave developed mechanisms to counteract DC-mediated immu-
nity [44–48]. Similarly, infection of moDCs by HRV14 has been
demonstrated to lead to impaired moDC function resulting in
reduced T cell stimulatory capacity [49,50]. HRV14 ssRNA has been
shown to induce IFN-α secretion in these cells, while failing to
induce NF-κB-dependent expression of pro-inﬂammatory cyto-
kines [34]. In line with these ﬁndings, our data indicate, that SLFN
gene expression induced upon HRV14 infection of moDCs is
mainly attributable to type I interferon production. Sensing of
HRV14 ssRNA presumably occurs through the cytoplasmic pattern
recognition receptor RIG-I [34], since TLR7 is not expressed in
moDCs [51,52], whereas TLR8 stimulation is rather associated with
the induction of a pro-inﬂammatory cytokine milieu via MyD88-
dependent signaling [53]. PGN-mediated stimulation of TLR2 fur-
ther underlines the strong dependency of SLFN gene expression on
HRV time course (hours)
IFN-α time course (hours)
Fig. 3. SLFN family members are induced by HRV14 and IFN-α in moDCs. moDCs were
stimulated over a 24 h time course with (A) 1 TCID50/cell of HRV14 and (B) 100 U/
ml of IFN-α. Cells were lysed at the given time points and total RNA was isolated,
reverse transcribed and mRNA expression of the indicated genes was determined
via qPCR. Expression values were calculated relative to GAPDH as a reference gene
and normalized to unstimulated cells. Data is representative of two independent
experiments or three different donors. Error bars indicate mean7SD of technical
replicates. In some cases, SD is too small to be visible.
LPS time course (hours)
s
PGN time course (hours)
Fig. 4. SLFN family members are induced by LPS but only poorly by PGN stimulation.
moDCs were stimulated over a 24 h time course with (A) 1 μg/ml LPS and (B) 10 μg/
ml PGN. Cells were harvested at the given time points and mRNA expression of the
indicated genes was determined via qPCR. Expression values were calculated
relative to GAPDH as a reference gene and normalized to unstimulated cells. Data is
representative of two independent experiments or three different donors. Error
bars indicate mean7SD of technical replicates. Note, that for some bars SD is too
small to be discernible.
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The induction of ISGs via type I interferons depends on the
presence of interferon-stimulated response elements (ISREs) in
the promoter region of the ISG, enabling transcriptional activation
through binding of the ISGF3 transcription factor, which is a
complex of phospho-STAT1/STAT2 heterodimers and IRF-9 [35].
Bioinformatic analysis via MatInspector [54] revealed less than2 canonical ISRE sites for most human SLFN genes, which is con-
siderably lower than the 6 sites predicted for MxA. While this
numerical difference could explain the lower inducibility of SLFNs
compared to MxA via type I interferon, it is unclear, if these
canonical ISREs are both, necessary and sufﬁcient to induce SLFN
gene transcription, or whether other elements are involved in
interferon-dependent and -independent regulation of SLFN genes.
Further studies would be needed to clarify these open questions.
T cell activation time course (hours)
Fig. 5. Regulation of SLFNs during the activation of primary human T cells. T cells were activated with plate bound anti-CD3 (coated at 2 μg/ml) or a combination of anti-CD3
and anti-CD28 (2 μg/ml each) for (A) 6 h, 12 h and 24 h. (B) Cells were activated as above for 12 h in the presence or absence of 100 U/ml of IFN-α. SLFN gene expression was
determined via qPCR. Data is displayed relative to CD3E and is normalized to unstimulated controls. (C) T cells were activated in the presence or absence of IFN-α as indicated
above. T cell proliferation was measured on day 3 via [methyl-3H] thymidine incorporation. Error bars indicate mean7SD of technical replicates. Note, that in some cases SD
is too small to be discernible.
A. Puck et al. / Results in Immunology 5 (2015) 23–32 29
A. Puck et al. / Results in Immunology 5 (2015) 23–3230SLFN11 has been recently described as a potent inhibitor of
HIV-1 by interfering with viral protein synthesis [17]. Our data
indicate a typical type I interferon-dependent expression pattern
for this factor in human immune cells since mRNA levels were
inducible by HRV, LPS and IFN-α, but were rather insensitive to
PGN, IL-4/GM-CSF-mediated moDC differentiation or T cell acti-
vating stimuli. However, we found, that basal SLFN11 mRNA levels
were highest among all SLFNs in monocytes and moDCs (Fig. 1)
suggesting functional importance. High SLFN11 levels in CD4þ T
lymphocytes have been described to correlate with the control of
viral replication in HIV-infected individuals [20]. Although CD4þ T
cells are seen as the main viral reservoir during HIV infection,
latency may also be established in cells of the monocyte/macro-
phage lineage [55]. Thus, high SLFN11 expression in monocytes
and macrophages might be of similar importance in controlling
HIV infection.
Maturation of moDCs via LPS revealed differential mRNA
induction kinetics for SLFN5, SLFN11 and SLFN12 compared to
SLFN12L and SLFN13, indicating that transcriptional regulation of
SLFNs, although sharing many features with the expression pattern
of classical ISGs, might not be solely dependent on type I inter-
ferons. In fact, the further increase of SLFN12L and SLFN13 mRNA
levels observed at the late time point of LPS stimulation of moDCs,
is reminiscent of the concept of “inﬂammation suppressor genes”
[56], which suggests upregulation of negative-feedback regulators
following the initial rapid induction and decline of pro-
inﬂammatory mediators. It is tempting to speculate, that
SLFN12L and SLFN13 might interfere with a potentially pro-
inﬂammatory role of other SLFNs, by direct or indirect inhibition
of their function. Similar expression kinetics for murine Slfns have
been reported in LPS-stimulated bone marrow-derived macro-
phages [7], although our data do not indicate any correlation of
this differential expression pattern with the presence or absence of
the helicase domain, since it is present in genes with early (SLFN5,
SLFN11) as well as with late (SLFN13) expression peaks.
Maturation of moDCs via the TLR4 stimulus LPS or the TLR2
stimuli PGN/Pam3cys not only differs in its potential to induce
type I interferon but also in regard to T cell polarization via dif-
ferential IL-12p70 expression [57,58]. As a result, moDCs, which
are matured via TLR4 or TLR2 signals, promote Th1 and Th2
cytokine secretion, respectively, in co-cultured T cells [57]. This
divergent functional outcome is mirrored by the differential reg-
ulation of SLFN12 in LPS and PGN stimulated moDCs, suggesting
that high SLFN12 levels could be a marker for moDCs with high
Th1 polarizing capacity, while low levels would be indicative of
the capability to induce Th2 cells. If so, SLFN12 could be func-
tionally involved in polarizing moDC stimulatory capacity.
Murine Slfn1, Slfn2, Slfn5 and Slfn8 [1,3] have been described to
be downregulated during T cell activation, while Slfn3, Slfn4 and
Slfn9 [1,3,39] are induced by T cell activating stimuli. However,
direct effects on the growth of thymocytes and peripheral T cells,
respectively, have only been described for Slfn1 and Slfn8 trans-
genic mice, which both display reduced thymic cellularity [1,3].
Our own results obtained in human T cells suggest that most
human SLFNs are downregulated within 24 hours after activation
indicating that high expression levels might interfere with the
process of T cell activation or proliferation. Type I interferons have
been associated with the inhibition of cell growth and the induc-
tion of apoptosis in various cancer cell lines [59–62]. Their precise
role on T cell activation is less clear and might be context-
dependent, since type I interferons have been reported to promote
[63] as well as inhibit T cell expansion [64] or differentiation [65].
In our setting, the observed upregulation of SLFNs during IFN-α
stimulation of activated T cells could not be directly associated
with the inhibition of cell growth, since we did not observe
growth-inhibition of interferon-stimulated human T cells in vitro.Nevertheless, high basal expression levels of SLFN5 in resting T
cells followed by downregulation after activation-similar to the T
cell quiescence factor KLF2 [41,42]-suggest that SLFN5 might be
part of a complex array of factors involved in actively maintaining
T cell quiescence [40,66]. However, overexpression and RNAi
approaches would be necessary to clarify, whether SLFN5 or other
members of this protein family may indeed possess growth reg-
ulatory functions in human T cells.
In summary, we describe here for the ﬁrst time the expression
and regulation of SLFN family members in primary human
monocytes, moDCs and T lymphocytes. Our data indicates func-
tional roles of SLFN11, SLFN12L and SLFN13 in monocytes/moDCs,
whereas SLFN5 could be a regulator of human T cell activation.
Rapid downregulation of SLFN12 by various activation or differ-
entiation stimuli in different cell types suggests a generally inhi-
bitory role of this factor. Thus, we envisage that our study will
provide incentives for further work aiming to characterize the
functional role of SLFNs in primary human immune cells.Conﬂicts of interest
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